EVERSANA will team up with Amazon Web Services (AWS) to accelerate generative artificial intelligence (AI) use cases across the life sciences industry. Together, the organizations will seek to harness the power of generative AI to help pharmaceutical and life science manufacturers drive efficiencies and business value while improving patient outcomes. To meet the industry’s unique needs, EVERSANA and AWS will identify, develop and deploy high-impact solutions across the pharmaceutical commercialization value chain. EVERSANA will leverage its digital and AI innovation capabilities coupled with Amazon Bedrock — AWS’s fully managed service for building and scaling generative AI applications that make a selection of industry-leading foundation models (FMs) accessible via a simple API — to apply best-of-breed FMs as the companies work to solve customer challenges.
EVERSANA announced the launch of EVERSANA ORCHESTRATE™, the life science industry’s first end-to-end omnichannel solution focused on amplifying brand impact. It orchestrates “next best experience” commercialization services to simultaneously drive sales and patient outcomes. Informed by a global omnichannel advisory council of more than 20 pharmaceutical leaders and 40 subject matter experts, EVERSANA ORCHESTRATE leverages artificial intelligence (AI) and machine learning (ML) to apply a deep understanding of patient and provider needs. The solution aggregates and synthesizes pivotal data points to predict and capitalize on brand opportunities while reducing market waste. It serves as a seamless router of actionable data and deep insights across both personal and non-personal channels, providing brands with optimal touchpoint orchestration.
EVERSANA acquired pharmaphorum parent Healthware Group in a move that elevates the longstanding partnership between the companies, expands their geographic reach, and furthers their ambition to “reinvent” how the biopharma industry commercializes its products. The takeover will Healthware integrate with Eversana Intouch to create a “full-service global, award-winning agency network,” said the companies in a joint statement. Eversana Intouch is the US group’s global agency network, acquired in 2021 when it bought Intouch, and offers a range of services from pre-launch planning to measuring real-world value for patients. Adding Healthware and its 150-strong workforce in Italy, Finland, and the UK expands Eversana’s reach in Europe, as well as capabilities such as the application of artificial intelligence to marketing to help pharma, medical device, and emerging biotechs launch products, expand market access, and solve geographic and market-specific challenges.
Fishawack Health announced that it is unifying under the new name and brand, Avalere Health. Avalere Health is purposefully built to be the leading, global commercialization partner for change-making healthcare companies looking to maximize the value of their portfolios while connecting patients to life-changing health solutions. Since its inception in 2001, the company has successfully acquired and integrated 19 best-in-class healthcare agencies and consultancies across North America, Europe and the Asia-Pacific region. Its diverse expertise spans the entire healthcare ecosystem, with its teams collaborating across the globe to accelerate innovation and maximize impact on human lives.
OptimizeRx Corp. signed an agreement to acquire Healthy Offers, Inc., dba Medicx Health, a leading healthcare consumer-focused omnichannel marketing and analytics company. The transaction purchase price is $95 million, and certain members of Medicx’s management plan to invest approximately $10.5 million of their proceeds into the company’s common stock. Closing is expected during the fourth quarter of 2023. The acquisition of Medicx further advances OptimizeRx’s mission to create a more informed and empowered healthcare community using new technology solutions.
PharmaCord announced that PharmaCord Lynk™, PharmaCord’s proprietary technology system, has achieved certification from Surescripts® for electronic prior authorization. This certification is part of the National Council for Prescription Drug Programs, V2017071. PharmaCord continues to offer biopharmaceutical manufacturers and life science companies its upgraded state-of-the-art ePA solutions, maintaining a smoother and more efficient process that ultimately benefits all key stakeholders.
Thea Pharma announced the launch and availability of Iyuzeh (latanoprost ophthalmic solution) 0.005% in the US market. Iyuzeh, which received FDA approval in December 2022, is the first and only preservative-free latanoprost for patients with primary open-angle glaucoma (POAG) and ocular hypertension (OHT) in the US. Iyuzeh is available for as little as $60 for a 30-day supply through programs with PhilRx and the Thea Savings Card. PhilRx is a service that provides a convenient way to prescribe IYUZEH, with the medication shipped for free and directly to a patient’s door. This service offers online and phone support for both eye care professionals and their patients.
Takeaway: AMI’s annual Specialty Hub Service Providers Report provides comprehensive business intelligence on more than 70 companies